IQVIA
IQV
168,40 €
Share price
-1.62%
Change (1 day)
-23.23%
Change (1 year)
Revenue for IQVIA (IQV)
Revenue in 2025 (TTM): €14.39 Billion
According to IQVIA's latest financial reports the company's current revenue (TTM 
) is €13.41 Billion. In 2024 the company made a revenue of €14.80 Billion an increase over the revenue in the year 2023 that were of €13.55 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for IQVIA from 2012 to 2025
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2025 (TTM) | €14.39 B | -2.77% |
| 2024 | €14.80 B | 9.22% |
| 2023 | €13.55 B | 0.9% |
| 2022 | €13.43 B | 9.66% |
| 2021 | €12.25 B | 32.66% |
| 2020 | €9.23 B | -6.7% |
| 2019 | €9.89 B | 8.75% |
| 2018 | €9.10 B | 11.91% |
| 2017 | €8.13 B | 24.37% |
| 2016 | €6.53 B | 24.61% |
| 2015 | €5.24 B | 16.89% |
| 2014 | €4.48 B | 21.58% |
| 2013 | €3.69 B | 0.39% |
| 2012 | €3.67 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | €0.12 B | -99.09% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |